Benefits of adjuvant treatment including trastuzumab in HER2-positive pT1a-bN0M0 breast cancer: a systematic review and meta-analysis

BACKGROUND: Although trastuzumab has been shown to be beneficial for treating patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, information regarding its benefits is limited to very low-risk cases with tumours ≤1 cm and without lymphatic metastases (pT1abN0). The...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hye Yoon, Shin, In-Soo, Rim, Chai Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154451/
https://www.ncbi.nlm.nih.gov/pubmed/32309334
http://dx.doi.org/10.21037/atm.2020.01.81

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154451/
https://www.ncbi.nlm.nih.gov/pubmed/32309334
http://dx.doi.org/10.21037/atm.2020.01.81

Ejemplares similares